Schinazi R F, McMillan A, Cannon D, Mathis R, Lloyd R M, Peck A, Sommadossi J P, St Clair M, Wilson J, Furman P A
Veterans Affairs Medical Center, Decatur, Georgia 30033.
Antimicrob Agents Chemother. 1992 Nov;36(11):2423-31. doi: 10.1128/AAC.36.11.2423.
2',3'-Dideoxy-5-fluoro-3'-thiacytidine (FTC) has been shown to be a potent and selective compound against human immunodeficiency virus type 1 in acutely infected primary human lymphocytes. FTC is also active against human immunodeficiency virus type 2, simian immunodeficiency virus, and feline immunodeficiency virus in various cell culture systems, including human monocytes. The antiviral activity can be prevented by 2'-deoxycytidine, but not by other natural nucleosides, suggesting that FTC must be phosphorylated to be active and 2'-deoxycytidine kinase is responsible for the phosphorylation. By using chiral columns or enzymatic techniques, the two enantiomers of FTC were separated. The (-)-beta-enantiomer of FTC was about 20-fold more potent than the (+)-beta-enantiomer against human immunodeficiency virus type 1 in peripheral blood mononuclear cells and was also effective in thymidine kinase-deficient CEM cells. Racemic FTC and its enantiomers were nontoxic to human lymphocytes and other cell lines at concentrations of up to 100 microM. Studies with human bone marrow cells indicated that racemic FTC and its (-)-enantiomer had a median inhibitory concentration of > 30 microM. The (+)-enantiomer was significantly more toxic than the (-)-enantiomer to myeloid progenitor cells. The susceptibilities to FTC of pretherapy isolates in comparison with those of posttherapy 3'-azido-3'-deoxythymidine-resistant viruses in human lymphocytes were not substantially different. Similar results were obtained with well-defined 2',3'-dideoxyinosine- and nevirapine-resistant viruses. (-)-FTC-5'-triphosphate competitively inhibited human immunodeficiency virus type 1 reverse transcriptase, with an inhibition constant of 2.9 microM, when a poly(I)n.oligo(dC)19-24 template primer was used. These results suggest that further development of the (-)-Beta-enantiomer of FTC is warranted as an antiviral agent for infections caused by human immunodeficiency viruses.
2',3'-二脱氧-5-氟-3'-硫代胞苷(FTC)已被证明是一种在急性感染的原代人淋巴细胞中对1型人类免疫缺陷病毒有效的选择性化合物。FTC在包括人单核细胞在内的各种细胞培养系统中对2型人类免疫缺陷病毒、猴免疫缺陷病毒和猫免疫缺陷病毒也具有活性。2'-脱氧胞苷可阻止其抗病毒活性,但其他天然核苷则不能,这表明FTC必须磷酸化才能发挥活性,且2'-脱氧胞苷激酶负责磷酸化过程。通过使用手性柱或酶技术,FTC的两种对映体得以分离。在人外周血单核细胞中,FTC的(-)-β-对映体对1型人类免疫缺陷病毒的活性比(+)-β-对映体高约20倍,并且在缺乏胸苷激酶的CEM细胞中也有效。消旋FTC及其对映体在浓度高达100微摩尔时对人淋巴细胞和其他细胞系无毒。对人骨髓细胞的研究表明,消旋FTC及其(-)-对映体的半数抑制浓度>30微摩尔。(+)-对映体对髓系祖细胞的毒性明显高于(-)-对映体。与人类淋巴细胞中治疗后3'-叠氮-3'-脱氧胸苷耐药病毒相比,治疗前分离株对FTC的敏感性没有实质性差异。对明确的2',3'-二脱氧肌苷和奈韦拉平耐药病毒也获得了类似结果。当使用聚(I)n·寡聚(dC)19-24模板引物时,(-)-FTC-5'-三磷酸竞争性抑制1型人类免疫缺陷病毒逆转录酶,抑制常数为2.9微摩尔。这些结果表明FTC的(-)-β-对映体作为一种抗人类免疫缺陷病毒感染的抗病毒药物值得进一步开发。